sequence stringlengths 4 17.9k | seq_id stringlengths 1 6 | pn stringclasses 996
values | title stringclasses 871
values | pbdt int64 20.2M 20.3M | status int64 1 225 ⌀ | family_country listlengths 1 55 | modified_info stringlengths 112 8.31k ⌀ |
|---|---|---|---|---|---|---|---|
gcuccagccagcagcaugg | 2594 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
acacagcuuccgucuggac | 965 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
uccauugaauggacaguuu | 2190 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
aucaucccugugcggguua | 3638 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
aucaucccugugcggguua | 3483 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
aucaucccugugcggguua | 549 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
caucaucuuggggcaguuu | 742 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
caacuucugcaggaggcca | 3055 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
ucgauagguguggucauuc | 1464 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
cugcccauucuuaucccga | 278 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
gggagucugaauagucauc | 1546 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
uauuaaggcgccggcgauc | 557 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
cucaaagaaacgaucauac | 1390 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
ccuuuccuggcagcacaga | 1083 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
cucugauucugggaaccau | 1989 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
gccgagugccaaaguacau | 2071 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
caguggacaaugcccgagg | 820 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
gccaggcugugagauuuac | 1957 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
uuuugggcauagaacaaca | 712 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
cauggaauuuacuaguucc | 1792 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
cauuugaaacuguccauucaa | 3391 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
cauuugaaacuguccauucaa | 457 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
cauuugaaacuguccauucaa | 3546 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
agaacugcugcaaagaucu | 2131 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
acaucacacagcucuucca | 2224 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
aaagcaggcaaaucucugu | 681 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
uguuuuccucgugcuuugu | 1849 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
gcuggcuggagcccuggag | 2607 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
ccagggcuccagccagcag | 2604 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
uaugcccaaaacugcccca | 727 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
ccucucugccacccaugcu | 2569 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
gagcccuggagucugugcg | 2623 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
aaaguguccauaacugccc | 1686 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
cccguggguggcgacucau | 1640 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
aggccggcauccauuagca | 2754 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
uuucuuugagaaaaaaauu | 1403 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
gugauguggcccaugaguu | 360 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
ggguggcagagagguggug | 2560 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
cucaagacuggcuuugcag | 1130 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
uaagaugagacacucaaacuggu | 4793 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
aucaucccugugcggguug | 2839 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
agcaaguugguaucugcuc | 3187 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
aaugacucaacccucuuca | 1895 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
cugcaguggacaaugcccg | 826 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
aaaugauguccauuuuugg | 249 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
ugaagaacuuccaggacau | 1231 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
atatctttgctcccagtttca | 2071 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
atatctttgctcccagtttca | 2071 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
atatctttgctcccagtttca | 2071 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
atatctttgctcccagtttca | 2932 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
atatctttgctcccagtttca | 2932 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
atatctttgctcccagtttca | 2932 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
atatctttgctcccagtttca | 1867 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
atatctttgctcccagtttca | 1867 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
atatctttgctcccagtttca | 1867 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
atatctttgctcccagtttca | 3136 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
atatctttgctcccagtttca | 3136 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
atatctttgctcccagtttca | 3136 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tatcacattactcatgaatacat | 3528 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tatcacattactcatgaatacat | 3528 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tatcacattactcatgaatacat | 3528 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tatcacattactcatgaatacat | 2463 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tatcacattactcatgaatacat | 2463 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tatcacattactcatgaatacat | 2463 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gaagtcttccatcagcagtgatt | 1568 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gaagtcttccatcagcagtgatt | 1568 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gaagtcttccatcagcagtgatt | 1568 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gaagtcttccatcagcagtgatt | 1604 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gaagtcttccatcagcagtgatt | 1604 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gaagtcttccatcagcagtgatt | 1604 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tgaccttttctcaaagctgtaca | 1171 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tgaccttttctcaaagctgtaca | 1171 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tgaccttttctcaaagctgtaca | 1171 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
ttgtgtgccaaagtgcactctga | 187 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
ttgtgtgccaaagtgcactctga | 187 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
ttgtgtgccaaagtgcactctga | 187 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
ttgtgtgccaaagtgcactctga | 457 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
ttgtgtgccaaagtgcactctga | 457 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
ttgtgtgccaaagtgcactctga | 457 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
ttgtgtgccaaagtgcactctga | 907 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
ttgtgtgccaaagtgcactctga | 907 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
ttgtgtgccaaagtgcactctga | 907 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
ttgtgtgccaaagtgcactctga | 637 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
ttgtgtgccaaagtgcactctga | 637 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
ttgtgtgccaaagtgcactctga | 637 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcggtgcttccctttcactga | 1892 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcggtgcttccctttcactga | 1892 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcggtgcttccctttcactga | 1892 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcggtgcttccctttcactga | 2957 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcggtgcttccctttcactga | 2957 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcggtgcttccctttcactga | 2957 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gaagaccaaagagcaagtgaa | 1842 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gaagaccaaagagcaagtgaa | 1842 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gaagaccaaagagcaagtgaa | 1842 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gaagaccaaagagcaagtgaa | 2907 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gaagaccaaagagcaagtgaa | 2907 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gaagaccaaagagcaagtgaa | 2907 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gaagaccaaagagcaagtgaa | 3125 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gaagaccaaagagcaagtgaa | 3125 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gaagaccaaagagcaagtgaa | 3125 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.